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response. These novel pressed pSi-PCL materials have potential for delivery of both small and 
large drugs that can be released in active form, and can support the growth of mammalian 
cells.  
Keywords: polycaprolactone; nanostructured porous silicon; composite biomaterial; drug 
release; cell proliferation; inflammation 
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Highlights 
 We fabricated novel pressed porous silicon-polycapralactone composite materials 
 The materials supported the attachment and growth of mammalian cells 
 Small molecule drugs and biologics were loaded into the composites 
 The materials elicited a weak foreign body response under the rat conjunctiva 
 Composite materials may be of use for the transfer of cells and drugs to the ocular 
surface 
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ABSTRACT 
Dysfunction of corneal epithelial stem cells can result in painful and blinding disease of the 
ocular surface. In such cases, treatment may involve transfer of growth factor and normal 
adult stem cells to the ocular surface. Our purpose was to develop an implantable scaffold for 
the delivery of drugs and cells to the ocular surface. We examined the potential of novel 
composite biomaterials fabricated from electrospun polycaprolactone (PCL) fibres into which 
nanostructured porous silicon (pSi) microparticles of varying sizes (150-250 µm or <40 µm) 
had been pressed. The PCL fabric provided a flexible support for mammalian cells, whereas 
the embedded pSi provided a substantial surface area for efficient delivery of adsorbed drugs 
and growth factors. Measurements of tensile strength of these composites revealed that the pSi 
did not strongly influence the mechanical properties of the polymer microfiber component for 
the Si loadings evaluated. Human lens epithelial cells (SRA01/04) attached to the composite 
materials, and exhibited enhanced attachment and growth when the materials were coated 
with fetal bovine serum. To examine the ability of the materials to deliver a small-drug 
payload, pSi microparticles were loaded with fluorescein diacetate prior to cell attachment. 
After 6 hours (h), cells exhibited intracellular fluorescence, indicative of transfer of the 
fluorescein diacetate into viable cells and its subsequent enzymatic conversion to fluorescein. 
To investigate loading of large-molecule biologics, murine BALB/c 3T3 cells, responsive to 
epidermal growth factor, insulin and transferrin, were seeded on composite materials. The 
cells showed significantly more proliferation at 48 h when seeded on composites loaded with 
these biologics, than on unloaded composites. No cell proliferation was observed on PCL 
alone, indicating the biologics had loaded into the pSi microparticles. Drug release, measured 
by ELISA for insulin, indicated a burst followed by a slower, continuous release over six 
days. When implanted under the rat conjunctiva, the most promising composite material did 
not cause significant neovascularization but did elicit a macrophage and mild foreign body 
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1. Introduction 
Porous silicon (pSi) shows potential as a biocompatible scaffold for applications in 
orthopaedics (Li et al., 1998; Coffer et al., 2005; Whitehead et al., 2008; Anderson et al., 
2010), oncology (Zhang et al., 2005; Mann et al., 2011; Park et al., 2011) and ophthalmology 
(Low et al., 2006; Cheng et al., 2008; Low et al., 2009; Kashanian et al., 2010). For use in 
ophthalmic implants designed to deliver drugs or cells to the eye, the advantages of pSi 
include its large surface area for drug-loading and cell attachment, and good ocular 
biocompatibility (Low et al., 2009; Kashanian et al., 2010). However, pSi is somewhat 
inflexible, is opaque, and shards of the membrane form of the material exhibit sharp edges. 
We have previously demonstrated that a composite material comprising a soft polymer such 
as polycaprolactone (PCL) encasing pSi particles mitigated some of these issues (Kashanian et 
al., 2010). Nevertheless, challenges with drug loading and release remained. Here, we 
describe a novel dual-function composite of pSi and PCL, pressed pSi-PCL. The composite 
consists of an electrospun (non-woven) PCL fabric with nanostructured pSi microparticles 
pressed into the outside of the fibres. An advantage of the newer composites is that drugs, 
including biologics such as proteins and peptides, can be loaded into the pSi particles 
(McInnes et al., 2015) after fabrication of the PCL material, thereby avoiding exposure to heat 
and solvents. 
 Our focus is on disorders that result in loss or dysfunction of the adult corneal 
epithelial stem cells normally residing at the limbus, at least in humans (Notara et al., 2010; 
Ordonez & Girolamo, 2012; Joe & Yeung, 2014). A number of biomaterials have been 
assessed as scaffolds (Feng et al., 2014) for transfer of corneal epithelial stem cells and 
transient-amplifying cells to the ocular surface (Joe & Yeung, 2014), and silk fibroin shows 
promise for corneo-limbal reconstruction (Harkin et al., 2011; Bray et al., 2012). We aimed to 
engineer a biomaterial suitable for ocular surface repair. Herein, we assessed the loading and 
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release of both small molecule and macromolecular drugs into pressed pSi-PCL composite 
materials, and their ability to support mammalian cell attachment and growth. Implantation of 
the material beneath the conjunctiva of rats was performed to assess biocompatibility. 
 
2. Materials and methods 
2.1 Reagents 
Ophthalmic balanced salt solution (BSS) was obtained from Alcon Laboratories Inc (Fort 
Worth, TX, USA). Dulbecco’s Modified Eagle’s Medium (DMEM) was sourced from JRH 
Bioscience (Lanexa, KA, USA). L-glutamine, penicillin, streptomycin sulphate, insulin, 
transferrin and sodium selenite were all obtained from Invitrogen (Mount Waverley, VIC, 
Australia). Epidermal growth factor (EGF) was obtained from ProSpec-Tany TechnoGene 
Ltd. (Ness-Ziona, Israel). Chloroform, fluorescein diacetate (FDA) and ethanol were obtained 
from Sigma Chemical Co. (St Louis, MO, USA). Fetal bovine serum (FBS) was obtained 
from Bovogen Biologicals (Essendon, VIC, Australia). Hoechst 33342 dye was purchased 
from Molecular Probes (Eugene, OR, USA). 
 
2.2 Fabrication of pressed pSi-PCL composites 
PCL was obtained from Aldrich (Milwaukee, WI, USA). Nonwoven fabrics of PCL were 
prepared as described previously (Kashanian et al., 2010; Fan et al., 2011). Briefly, a 25% by 
weight solution of PCL (MW 65 kDa) in chloroform was placed in a 5 ml glass syringe fitted 
with a 21 gauge needle, with an applied potential of 20 kV and tip to grounded Al collector 
distance of approximately 20 cm. Samples of pSi were generously provided by Professor L 
Canham and Dr A Loni, pSiMedica Ltd. Films of pSi were first produced by electrochemical 
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anodization of p-type (0.01-0.02 Ohm cm) single-crystal silicon wafers in hydrofluoric acid, 
followed by separation of a pSi membrane from the bulk Si and subsequent milling of the 
membrane. The particles were sieved to two size ranges: 150-250 µm, and <40 µm. For 
fabrication of composite materials, two different methods were evaluated. Method A. To 
embed pSi microparticles in the outer surface of microfibres of PCL, the particles were 
warmed to a temperature above the polymer melting point, followed by brief exposure to the 
PCL fabric, forcing a modest blending between the contacting interfaces. Specifically, pSi 
particles were heated in an oven at 110°C, then immediately transferred to a glass plate. A 1x1 
cm
2
 piece of PCL fabric was physically pressed on to the hot particles. The hot particles 
caused localized melting of the PCL fibres and thus resulted in the pSi being partially 
embedded in the polymer. Loadings of the order of 5-6% pSi by mass were obtained, with 
retention of PCL fibre morphology. Method B. Improved embedding of pSi microparticles in 
the PCL was achieved by the brief addition of chloroform to pSi microparticles after removal 
from the oven, resulting in a surface etch/dissolution of the PCL surface and better adhesion 
of the pSi particles to the PCL matrix. This processing step was followed by an additional 
electrospinning event, to physically entrap more pSi into the composite. Specifically, pSi 
particles were heated in an oven at 220°C for 10 minutes (min), then transferred to a cold 
glass plate. One drop of chloroform was added to the pSi and quickly mixed. After ~10 sec, a 
1x1 cm
2
 piece of PCL fabric was physically pressed on to the moist pSi particles. An 
additional thin layer of PCL fibres was then generated on to the pSi-PCL, resulting in the 
formation of a “net”. Loadings of the order of 32-34% pSi by mass were obtained, with 
retention of PCL fibre morphology. 
 
2.3 Characterization by electron microscopy 
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Nanoporous features in individual pSi microparticles were imaged by transmission electron 
microscopy (TEM) using a JEOL JEM 2100 and by scanning electron microscopy (SEM) 
using a JEOL JSM 6400. Fibre diameter and scaffold morphology in the pSi-PCL composites 
were also characterized by SEM. 
 
2.4 Characterization of biomaterial tensile strength 
Evaluation of tensile strength was carried out on selected pSi-PCL composites (as well as PCL 
fiber only controls) with an approximate cross-sectional area of 1 x 10
-6
 m
2
 using a Hampden 
H-6310 tension-testing machine (Hampden Engineering Corp., East Longmeadow, MA, 
USA). 
 
2.5 Small molecule loading into pSi microparticles and quantification of drug release 
For loading of FDA, 10 mg of pSi microparticles were immersed in a solution of 250 g/L 
FDA in chloroform for 1h at 70°C. Percent loading of FDA by mass was assessed by 
thermogravimetric analysis (TGA) using a Seiko Instruments TG/DTA 220 unit. To quantify 
FDA release (Mogal et al., 2014), FDA-loaded pSi microparticles were immersed in 100 μL 
of PBS pH 7.4. Samples were assayed in triplicate and stored in an incubator at 37°C between 
sampling events. For each sampling event, the microparticles were centrifuged, and the entire 
supernatant was withdrawn for analysis and replaced with 100 μL of fresh PBS. The sample to 
be tested was diluted into 900 μL of 0.1 M NaOH and the fluorescein peak at 490 nm was 
read on a NanoDrop UV-Vis (Thermo Scientific, Wilmington, DE, USA) under ambient 
conditions. The total FDA concentration was determined by summation of the 490 nm 
readings at all time-points. The earlier time points were then presented as a percentage of total 
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accumulated release. 
 
2.6 Cell attachment and culture on pSi-PCL composite material 
Pieces of composite material were sterilised by immersion in 70% ethanol for 5 min, then 
washed three times with sterile Dulbecco’s A phosphate buffered saline (PBS), pH 7.2. The 
pieces were then transferred into sterile 96-well plates (Becton Dickinson Labware, Franklin 
Lakes, NJ, USA) and held in place by polytetrafluoroethylene O-rings. Prior to seeding cells, 
the material was immersed in DMEM containing 10% FBS, 100 IU/ml penicillin, 100 µg/ml 
streptomycin sulphate and 0.29 mg/ml glutamine (complete medium) for 5 min. Human lens 
epithelial cells designated SRA01/04, the kind gift of Professor V. Reddy, Kellogg Eye 
Centre, University of Michigan, Ann Arbor, MI, USA, were seeded at 1x10
5
 cells per well in 
200 µl complete medium. Cells were maintained at 37°C with 5% CO2 in air for 6 or 24 h. 
 
2.7 Enhanced attachment and growth of cells on composite materials 
The ability of growth factors loaded in the pSi to enhance attachment and growth of cells was 
examined. Initial experiments focussed on the use of FBS. Composite materials were sterilised 
and washed as above, then incubated with FBS for 2 h at room temperature. Material 
incubated in serum-free medium was used as a control. FBS was removed and SRA01/04 cells 
were seeded as above. After 6 or 24 h of culture, the medium was replaced with complete 
medium containing 10 nM Hoechst 33342 dye and incubated for 30 min. Unbound dye was 
removed by washing three times with complete medium. The cells were imaged on an 
Olympus IX71 inverted microscope or mounted on a slide in complete medium and imaged on 
an Olympus BX50 fluorescence microscope. 2D blind deconvolution was applied using 
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AutoDeblur 7.5.4 image deconvolution software (MediaCybernetics, San Diego, CA, USA) to 
improve image sharpness. 
 
2.8 Loading and release of insulin, transferrin, selenite and EGF into and from pSi-PCL 
composite materials 
Pieces of composite material were transferred to a 48 well plate, air-dried and exposed to UV 
radiation in a laminar air-flow hood for 5 min. Test composites were incubated in 500 µl of 1 
mg/ml insulin, 0.55 mg/ml transferrin, 0.67 µg/ml sodium selenite and 10 µg/ml EGF for 16 h 
at 4°C in a humidified box, to maintain activity of the biologics. Insulin, transferrin, and 
sodium selenite improve cell growth in serum-free or serum-low medium (Bottenstein et al., 
1979). Composites incubated in PBS were used as controls. The materials were washed 5 
times in sterile PBS and transferred to a 96 well plate. EGF is a potent mitogen for many 
mammalian cells, but not for SRA01/04 cells. Thus, BALB/c 3T3 cells (the kind gift of Dr. E. 
Lousberg, Adelaide University, Adelaide, Australia), which are EGF-responsive (Rubin et al., 
1991), were seeded on the materials at 2x10
4
 cells per well and incubated at 37°C and 5% 
CO2 in air for 48 h. The number of cells in each well was enumerated using the CellTiter 96® 
AQueous One Solution (Promega, Madison, WI, USA), according to the manufacturer’s 
instructions. 
The release of biologics from the pSi-PCL composite materials was first measured 
functionally, by their ability to induce proliferation in BALB/c 3T3 cells. pSi-PCL materials 
were loaded as described above. Conditioned medium was prepared by incubating the pSi-
PCL composite material in 400 µl DMEM at 37°C for 24 h, transferring to fresh medium for 
24 h and finally into fresh medium for 96 h. Unloaded pSi-PCL composite material was used 
as a control. A proliferation assay with BALB/c 3T3 cells was performed using the CellTiter 
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96® AQueous One Solution assay as described above, with 50 µl conditioned medium used in 
place of the pSi-PCL composite materials. Next, the release of insulin from the composite 
materials was measured. Materials were loaded with insulin, transferrin, and selenite as above 
and incubated in 200 µl serum free DMEM in a 97 well plate at 37 °C. Samples were taken at 
the end of day 1, day 2 and day 6. The medium was replaced with fresh serum-free DMEM at 
each time point. The amount of insulin in the conditioned medium was assayed using the 
Insulin Human ELISA kit (Abcam, Cambridge, MA, USA), according to the manufacturer's 
instructions. 
 
2.9 Biocompatibility of composite materials in the rat eye 
All animal studies adhered to the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research and approval for experimentation was obtained from the institutional Animal 
Welfare Committee of Flinders University. Inbred Sprague-Dawley rats were bred within the 
institution, maintained in 50% humidity with a 12 h light-dark cycle, and were allowed access 
to food and water ad libitum.  
 Composite materials were cut into 2x2 mm
2
 pieces, immersed in 70% ethanol for 5 
min, washed in sterile ophthalmic BSS and exposed to UV radiation overnight. Animals were 
anaesthetised using inhaled isoflurane in 2 L/min oxygen, delivered via a nose-cone. A 
subconjunctival pocket was created by blunt dissection of the superior, temporal and inferior 
conjunctiva of the right eye of each of 6 rats. A piece of the composite material was placed in 
each pocket and secured with interrupted 10-0 monofilament nylon sutures (Alcon 
Laboratories, Fort Worth, TX, USA). Chloromycetin ointment 1% (Aspen Pharmaceuticals, St 
Leonards, Australia) was applied and the eyelid was sutured shut for 24 h. In a further 3 rats, 
mock surgery was performed, without implantation of the biomaterial (suture-only controls). 
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Eyes were monitored weekly at the operating microscope for 8 weeks, at which time the rats 
were euthanized. Enucleated eyes were fixed in buffered formalin, embedded in paraffin wax, 
sectioned at 5 μm, and stained with haematoxylin and eosin (H&E) for end-point histology. 
Sections were assessed at the light microscope by a qualified pathologist (SK). 
 
3. Results 
3.1 Composite structure 
High porosity pSi (81%) was used in all composite materials. The pore diameter of this pSi 
was in the range of 10-20 nm as determined by high resolution TEM (Fig. 1A, B). In 
composites produced by method A (pSi-PCL material A), brown-black pSi particles were 
apparent by visual inspection but pSi loading was relatively low, at 5-6% by mass (Fig. 1C). 
In composites produced by method B (pSi-PCL material B), a nearly continuous pSi film was 
evident to the unaided eye (Fig. 1D), with significant pSi loading of 32-34% by mass. Two 
different pSi particle size ranges were utilized in scaffold preparation. Scanning electron 
micrographs of composites produced by method A are illustrated in Fig. 1E and G (pSi 
particles 150-250 μm and <40 μm, respectively) and those produced by method B are shown 
in Fig. 1F and H (pSi particles 150-250 μm and <40 μm, respectively).  
 The effect of pSi particle loading on the tensile strength of these composites 
was also evaluated. A PCL-only microfiber control sample exhibited a value of 1.8 ± 0.4 
MPa; Method A pSi-PCL composite (5-6% Si), 1.2 ± 0.2 MPa; Method B pSi-PCL composite 
(32-34% Si), 1.6 ± 0.2 MPa. Thus the presence of the pSi particles embedded on the outer 
surface of the PCL does not significantly impact the mechanical strength of these relatively 
small microfibers. 
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3.2 Small drug loading into and release from pSi-PCL composite materials 
The model small molecule drug FDA was loaded into pSi-PCL material A. The percent 
loading of FDA by mass, as assessed by thermogravimetric analysis, was 7.8% of pSi particle 
mass for larger pSi particles (150-250 µm) and 10.9% for the smaller particles (<40 µm). The 
rate of drug release was then measured (Fig. 2). The majority of the FDA release occurred 
within the first 4 h: 63% and 50% for the larger (150-250 μm) and smaller (<40 µm) pSi 
particles, respectively. Release then slowed over the remainder of the two-day period, 
reaching 92% for the composite pressed with the larger pSi microparticles and 75% for the 
composite pressed with the smaller pSi microparticles at 48 h. 
 
3.3 Transfer of FDA to cells grown on pSi-PCL composite materials 
Using pSi-PCL material A, the feasibility of transferring drugs from the loaded pSi 
component of the material into cells was assessed. FDA is itself non-fluorescent, but 
intracellular enzymatic cleavage converts FDA to the fluorescent product fluorescein, which 
accumulates within the cells (Rotman et al., 1966). This property allows assessment of cell 
viability, as the esterase required for cleavage is intracellular and is only active in live cells. A 
human lens epithelial cell line, SRA01/04 was used as a model mammalian ocular cell type. 
Attachment of SRA01/04 cells to the composites was observed at 6 h after seeding. The cells 
appeared evenly distributed and were present on the PCL fibres as well as pSi particles. 
Transfer of FDA to the cells was confirmed by the detection of fluorescein in all FDA-loaded 
materials, but not in the unloaded control material (Fig. 3A). Detection of fluorescein 
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indicated that the cells were viable. Compared with the material with smaller (<40 µm) 
microparticles (Fig. 3B), the fluorescent signal was stronger in the material with the larger 
(150-250 µm) microparticles (Fig. 3C).  
3.4 Enhanced attachment and growth of cells on FBS loaded composite material 
Loading of peptide or protein drugs into the pSi composite materials was performed with pSi-
PCL prepared by method B, to maximise macromolecular drug loading. Although cell 
attachment to uncoated pSi-PCL material B was observed at 6 h, there was little evidence of 
cell growth at 24 h (Fig. 4A, 4C). FBS, a model mixture of growth factors, has previously 
been shown to improve mammalian cell attachment to pSi membranes (Low et al., 2006). 
Enhancement of cell attachment to, and growth on, pSi-PCL material B composites that had 
been loaded with FBS was next assessed. Coating with FBS improved cell attachment and 
growth of SRA01/04 cells (Fig. 4B, 4D). The cells colonised the available surface area on the 
coated materials by 24 h and as before, grew on both the PCL fibres and the pSi particles. 
 
3.5 Loading and release of biologics in active form from composite materials post-fabrication 
All subsequent experiments were performed with composites prepared by method B into 
which the larger size range of pSi microparticles (150-250 µm) had been pressed, to maximise 
drug loading. The functional efficacy of specific biologics loaded into pSi-PCL material B on 
attached cells was next assessed. A mixture of epidermal growth factor, insulin, transferrin 
and sodium selenite was tested, as this combination of biologics induces proliferation in 
serum-deprived murine BALB/c 3T3 fibroblasts. Cells seeded on biologic-loaded and washed 
pSi-PCL material B showed significantly more proliferation than cells grown on unloaded 
composite material (Fig 5A). Cells seeded on polymer PCL fibres without pSi but pre-
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incubated with biologics did not show increased proliferation, indicating the biologics had 
loaded into the pSi microparticle component of the composite material. 
The release of loaded epidermal growth factor, insulin, transferrin and sodium selenite 
into cell culture medium was demonstrated by the effect of this culture medium on the 
proliferation of serum-deprived BALB/c 3T3 cells. The PCL-only material was not used in 
this experiment, as the previous experiment had demonstrated the biologics had loaded only 
into the pSi component of the composite material. Release was monitored over 6 days with 
samples taken on day 1, day 2 and a third sample consisting of release from days 3-6. DMEM 
conditioned by incubation of epidermal growth factor, insulin, transferrin and sodium selenite 
loaded pSi-PCL composite materials induced proliferation in BALB/c 3T3 cells (Fig 5B), in 
comparison with medium conditioned with unloaded pSi-PCL. Samples taken on day 1 of the 
release elicited the largest proliferative response, indicating a large amount of the loaded 
biologics had been released on day 1. However samples collected between days 3-6 also 
induced cell proliferation, indicating the continuing release of growth factors over this time-
frame.  
Finally, the release of insulin from the material was quantified by ELISA over 6 days, 
with samples taken on day 1, day 2 and a third sample consisting of release from days 3-6, as 
before. More insulin was released from the composite materials on day 1 than thereafter 
(Table 1). The rate of release decreased over time, in keeping with the observations from the 
functional release assay above. Taken together, these data suggested an initial burst release of 
the epidermal growth factor, insulin, transferrin and sodium selenite, followed by a slow 
release as the pSi microparticles dissolved.  
 
3.6 Biocompatibility of materials in the rat eye 
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Unloaded pSi-PCL B material was implanted under the conjunctiva of adult inbred Sprague-
Dawley rats to investigate in vivo biocompatibility. Immediately after implantation, pSi 
particles were visible at the operating microscope (Fig. 6A) but had dissolved by 8 weeks, at 
which stage the PCL fabric was still visible (Fig 6B). Vessels grew towards and encircled the 
sutures (Fig 6B). At 8 weeks post implantation, the animals were euthanized and their eyes 
were collected for histological analysis. At end-point histology, the position of the implant 
was marked by a thin fibrous capsule, with some neovascularization observed around the site 
(Fig. 6C). A foreign body response mediated by macrophages and foreign body-type giant 
cells was also visible (Fig 6D). The neovascular response to the sutures in the suture-only 
control rats was similar to the response against the implants. Overall, the implants were well 
tolerated by the animals and did not cause significant acute inflammation or a lymphocyte-
predominant immune response. 
 
4. Discussion 
In this study, we developed a dual-purpose composite material of pSi and PCL suitable for the 
transfer of drugs and cells to the eye. We designed a straightforward method of pressing pSi 
microparticles on to a sheet of non-woven PCL fabric. Examination by SEM demonstrated 
that the pSi particles were partially embedded in the PCL but remained exposed on the 
surface, to permit drug loading after preparation of the composite material. This conferred a 
significant advantage over similar materials in which pSi particles were completely embedded 
within the PCL fibres (Kashanian et al., 2010), as exposure of many drugs to solvents or high 
temperatures during fabrication of the biomaterial would inevitably lead to drug denaturation 
and loss of activity. We further demonstrated that soaking the pSi particles in chloroform prior 
to pressing caused localised etching of the PCL fibres, improving attachment of pSi 
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microparticles, and that particle retention could further be improved by the deposition of a 
thin layer of PCL strands on top of the particles. Together, these improvements led to 
increased pSi particle loading compared with previous methods (Kashanian et al., 2010), 
providing a high drug loading capacity. The PCL fabric base conferred a degree of flexibility 
to the materials, while the addition of nanostructured pSi microparticles allowed the loading 
of both small drugs, as exemplified by fluorescein diacetate, and peptide or protein biologics, 
as exemplified by insulin. The presence of the pSi particles did not significantly alter the 
measured mechanical strength of the PCL. Observed tensile strength values were in the 1.2-
1.8 MPa range, consistent with literature values for high-porosity PCL scaffolds possessing 
fiber diameters in the micrometer range (Eshraghi & Das, 2010; Sant et al., 2011). 
 The small molecule FDA is non-fluorescent and readily taken up by cells. Intracellular 
esterases cleave FDA to the fluorescent product fluorescein, which is retained within living 
cells (Rotman et al., 1966). Human lens epithelial cells, chosen as a convenient source of 
ocular epithelial cells, when seeded on to composite PCL-pSi materials demonstrated green 
fluorescence, indicating that FDA released from the composites had been taken up and 
converted to fluorescein by viable cells. The cells grew on composite materials irrespective of 
pSi microparticle size. However, more fluorescent cells were observed on materials with 
larger (150-250 µm) rather than smaller (<40 µm) pSi particles, possibly because such 
particles were able to be loaded with more of the model drug. Cells growing on or near a pSi 
microparticle appeared brighter than more distant cells. The former cells would therefore have 
been exposed to higher local concentrations of FDA than the latter. 
 Human lens epithelial cells attached to, and grew upon, the pSi-PCL composite 
materials. A coating of FBS, which contains a cocktail of growth factors and proteins, 
improved cell attachment and growth, and cells colonised the available surface area within 24 
h. We also demonstrated loading and release of a mixture of biologic agents containing 
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epidermal growth factor, insulin and transferrin into the composite materials, using the 
proliferation of BALB/c 3T3 cells grown in serum-deprived medium (Bottenstein et al., 1979) 
as a readout. This functional assay confirmed that the biologics were released from the 
composites in an active form. PCL fabric without embedded pSi microparticles did not elicit 
cell proliferation, indicating that the proteins loaded into the pSi. The release profile of 
biologics from the composite materials was also investigated. Loaded pSi-PCL was incubated 
in cell culture medium, which was then used to induce proliferation of the BALB/c 3T3 cells. 
The release profile showed an initial burst release followed by a gradual release over 6 days, 
as the pSi particles dissolved. Such a time-frame is likely sufficient for transfer of corneal 
epithelial progenitor cells to the eye and their subsequent migration on to the ocular surface. 
 Use of the composite as an ocular implant requires it to be biocompatible in the eye. 
The biocompatibility of both pSi and PCL have previously been demonstrated individually 
(Low et al., 2009; Ang et al., 2006) and together as a composite material (Kashanian et al., 
2010) for use at the front of the eye. Different PCL composites have recently been tested as 
potential scaffolds for transplantation of retinal progenitor cell to the back of the eye (Baranov 
et al., 2014). Furthermore, PCL is an FDA-approved material. We assessed the 
biocompatibility of our novel pressed pSi-PCL composites by implantation under the rat 
conjunctiva, away from the visual axis. The flexibility of the material allowed for easy 
implantation into pockets created in the subconjunctival space by blunt dissection. 
Implantation of the materials did not cause significant inflammation. Moderate 
neovascularization was observed, however, the degree of neovascularization was similar in 
suture-only controls. A foreign body type response mediated by histiocytes and foreign body 
type macrophages was also observed, again similar to that observed in the suture-only 
controls. Overall, the materials demonstrated acceptable biocompatibility following 
implantation into the subconjunctival space in rats. 
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 Ex vivo expanded cells must be transferred to the eye on a scaffold (Pellegrini et al., 
1997), of which human amniotic membrane is the most commonly used (Tseng et al., 1998). 
Human amniotic membrane contains a number of growth factors (Meller et al. 2011). 
However, the use of human amnion is associated with regulatory issues, including the risk for 
transfer of infectious agents. We envision that our novel composite materials might serve as 
useful scaffolds for the transfer of cells and growth factors or drugs to the eye in ocular 
surface disease. 
 
5. Conclusions 
Pressed pSi-PCL is an easily fabricated composite material. The composite is versatile, being 
suitable for delivery of either drugs or cells, or both, to the eye. The pSi microparticles can be 
pre-loaded with drugs such as FDA before fabrication of the composite, and transfer of FDA 
to cells grown on the composites in vitro was demonstrated. Coating of the composite material 
at room temperature with FBS after fabrication was also possible, and resulted in enhanced 
ocular cell attachment and growth. Loading of biologic agents was demonstrated, and the 
biologics were released in an active form. This novel composite material provides several 
advantages over pSi or PCL alone, and is superior to previously-described composite 
materials for drug loading and release. The ability to load the material with growth factors and 
to support the attachment and growth of ocular epithelial cells suggest a potential application 
in the treatment of ocular surface disease. Other potential avenues of investigation with this 
composite material, such as its utility to act as an implantable niche for limbal stem cells, 
remain to be explored. 
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Figure legends 
Figure 1. Visualisation of pSi microparticles and pSi-PCL composite materials. (A and B) 
High resolution TEM image of pSi microparticles (81% porosity) utilized in the composites. 
Individual pores can be visualized between the dense, dark regions of the image. Scale bars = 
20 nm.  (C) and (D) Optical images of pSi/PCL fibre composites (2x1 cm
2
 pieces) prepared by 
method A (C) and method B (D). (E-H) SEM images of pSi /PCL fibre composites prepared 
by method A, with large (150-250 μm) pSi particles (E); method A, with small (<40 μm) pSi 
particles (F); method B, with large (150-250 μm) pSi particles (G); method B, with small (<40 
μm) pSi particles (H). Scale bar = 200 μm for (E) and (G); scale bar = 50 μm for (F) and (H). 
Figure 2. Fluorescein diacetate (FDA) release from loaded pSi microparticles. Filled squares: 
150-250 μm microparticles; unfilled circles: small <40 μm pSi microparticles (n=3). 
Figure 3. Fluorescein diacetate (FDA) uptake by SRA01/04 cells attached to pressed pSi-PCL 
composite materials 6 h after seeding on FDA loaded pSi-PCL composite materials. Cell 
nuclei stained with Hoechst 33342 (blue), cell cytoplasm stained with fluorescein (green), pSi 
particles (asterisk), scale bars = 50 µm; inserts show a high magnification image of the cells, 
scale bars = 10 µm. (A) No green fluorescence was observed in the unloaded materials; (B) 
FDA-loaded composite with <40 µm pSi particles showed faint green fluorescence; (C) FDA-
loaded composite with 150-250 µm pSi particles showed bright green fluorescence. Images 
were sharpened using AutoDeblur 7.5.4 image deconvolution software (MediaCybernetics, 
San Diego, CA, USA). 
Figure 4. Growth of SRA01/04 cells on FBS-coated and uncoated pSi-PCL composite 
materials. Images of SRA01/04 cells 24 h after seeding on pSi-PCL composite materials. (A) 
Uncoated pSi-PCL with <40 µm pSi; (B) FBS-coated pSi-PCL with <40 µm pSi; (C) 
uncoated pSi-PCL with 150-250 µm pSi; (D) FBS-coated pSi-PCL with 150-250 µm pSi. 
25 
Cells were observed on the pSi particles (asterisks) as well as on the polymer fibers (arrow). 
Cells showed poor attachment to uncoated materials but adhered to and colonized the FBS-
coated materials. Cell nuclei stained with Hoechst 33342 (blue), scale bar = 50 µm. 
Figure 5. Proliferation of BALB/c 3T3 cells in response to EGF-insulin, selenite and 
transferrin (EGF-ITS) released from pSi-PCL composite materials. (A) Proliferation of 
BALB/c 3T3 cells 48 h after seeding on pSi-PCL composite materials or PCL fibres loaded 
with EGF-ITS. Cells seeded on EGF-ITS loaded pSi-PCL showed significantly more 
proliferation than on unloaded composite material and loaded PCL *p=0.008. Cells seeded on 
EGF-ITS loaded PCL did not proliferate more than cells loaded on unloaded PCL, #p=0.095. 
(B) Proliferation of BALB/c 3T3 cells in response to medium incubated with EGF-ITS loaded 
pSi-PCL composite material. EGF-ITS loaded in pSi-PCL composite materials was released 
into cell culture medium. Medium conditioned with EGF-ITS loaded pSi-PCL composite 
material induced proliferation of cells compared to medium conditioned with unloaded pSi-
PCL. 
Figure 6. Subconjunctival implantation of pressed pSi-PCL composites in the rat. (A) and (B) 
Pressed pSi-PCL composite material implanted under the rat conjunctiva, immediately after 
implant and 8 weeks post implant respectively. Arrows mark the implants. A gauze swab is 
visible in the top left corner of image B (asterisk). The porous silicon particles were visible 
immediately after implantation but had completely dissolved at 8 weeks; (C) Haematoxylin & 
eosin stained section of a representative eye 8 weeks after implantation. A foreign body 
response mediated by macrophages and foreign body-type giant cells was observed; (D) 
Magnified view of the area delineated by the red box in (C), showing remnants of the 
composite material (arrow). (E) Response to the suture (arrow) was similar to the foreign 
body response against the implant. Scale bars (C) = 200 µm, (D) and (E) = 100 µm. 
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Table 1 Rate of release of insulin from loaded pSi-PCL material B 
_____________________________________________________ 
Day of release  Insulin release (ng insulin/mg pSi-PCL B) 
    mean ± standard deviation
1
 
_____________________________________________________ 
Day 1    91 ± 1.9 
Day 2    18 ± 0.7 
Days 3-6     6 ± 3.0 
_____________________________________________________ 
1
 Means of 3 biological replicates (individual pieces of pSi-PCL); data are representative of 
two separate experiments. 
 
